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Our knowledge of the biology underlying the development of brain metastases (BM) from breast cancer has improved over the last
decade due to large clinical epidemiological studies, animal models of metastasis, and the use of high-resolution gene expression
proﬁling technologies. However, there are still major gaps in our understanding of the mechanisms utilized by breast cancer cells
to colonize the brain microenvironment, thus our arsenal of therapies remains relatively nonspeciﬁc, and the prognosis for breast
cancer patients with BM remains poor. Additional insights into these mechanisms are necessary to facilitate the development of
new preventive and curative therapeutic regimens to block this fatal disease. This paper aims to provide a general overview for the
readers of what has been achieved in this ﬁeld of research and its translation into clinical practice to date and to highlight exciting
new areas of research that promise to inform the development of new targeted therapies for BM.
1. An Overview of Metastasis
Metastasis, or metastatic disease, is the spread of cancer cells
fromoneorgantoadistantsiteviathebloodorlymph.Inthe
Nineteenth Century, Paget asked whether the distribution of
metastases in diﬀerent organs was simply a matter of chance.
He studied autopsy records of women with breast cancer, re-
vealing a nonrandom pattern of metastatic colonization. He
proposed a hypothesis that tumour cells (the “seed”) could
have speciﬁc aﬃnity for the microenvironments of certain
organs (the “soil”) [1]. This intriguing phenomenon is called
organotropism, and Paget’s hypothesis has now been repeat-
edly substantiated, with growing recognition of the impor-
tance of tumour cell interactions with the stromal microen-
vironment in supporting the establishment of metastases
(see below). For instance, analysis of large autopsy series has
showedthatlung,breast,melanoma,renal,andcoloncancers
are the most common primary tumours to metastasize to
the brain [2, 3]. There is a theory that the primary tumour
could contribute to priming “premetastatic niches” prior
to the establishment of micromestastases, thereby inﬂuenc-
ing organ tropism. Kaplan, Lyden, and colleagues’ analysis
of mouse models of lung metastasis implicated certain che-
mokines in this process, as well as mobilisation of haemat-
opoietic precursor cells to pre-metastatic sites [4], however
themechanismsunderlyingcreationofpre-metastaticniches
are not fully understood [5].
The metastatic process is very ineﬃcient. In order to
accomplish distant metastasis, tumour cells must ﬁrst detach
and/or escape from the primary site, then survive as circu-
lating tumour cells (CTCs) in the absence of the microenvi-
r o n m e n tc u e sw i t hw h i c ht h e yw e r ec o n c e i v e d .M o s tC T C s
are cleared from initial trapping sites within a few days.
Those that survive, and succeed in extravasating, engraft at a
distant site forming a micrometastasis, then may proliferate
to form a clinically signiﬁcant lesion after a fairly unpre-
dictableperiodoflatency(dormancy)spentmeetingrequire-
ments for cell division in the new microenvironment [6, 7].
The poorly understood “dormancy” phenomenon poses a
major challenge in metastasis management. Despite being
attractive drug targets (at least conceptually), CTCs and mi-
crometastasesareundetectablewithcurrenthematologicand
imaging technologies and are thought to be insensitive to
chemotherapeutics that target rapidly dividing cells.2 Genetics Research International
It is now becoming clear that only a very small propor-
tionofprimarytumourcellsarecapableofformingclinically
signiﬁcant metastatic lesion [8]. Because these cells share
critical features with normal stem cells (namely, multi-line-
age potential in reseeding a secondary tumour and self-
renewal), they have been called cancer stem cells (CSCs).
It is hypothesized that a complex combination of tumour
cell intrinsic and extrinsic processes eventually culminates in
the activation of dormant CSC proliferation at distant sites
[8]. Current evidence suggests that this includes continuing
tumour cell genetic evolution, adaptation, and selection of
those cells with signaling programs that best engage and
exploit the new microenvironment [9, 10]. Observations on
the temporal courses of metastasis, from diﬀerent primary
tumour types, provide some insight into the biology under-
lying these processes. For example, subsets of breast and
lung carcinomas show similar overall organ tropism (brain,
bone, lung, and liver), but strikingly diﬀerent progression
times, with distant relapse detected early in lung cancer (ma-
crometastases established within months of diagnosis), and
relatively late in breast cancer progression (after years to
decades of remission). This suggests early acquisition of
metastasis-enabling genetic alterations in lung cancer, in
contrast to a longer latency period as CTCs and/or microm-
etastases in breast cancer.
At least three categories of metastasis genes have been
proposed to facilitate the multistep metastatic cascade (re-
viewed in [11]): (1) “initiation” genes that facilitate detach-
ment (e.g., CDH2 (encodes N-Cadherin) and TWIST),e x -
tracellular matrix degradation (e.g., MMPs) or angiogenesis
(e.g., VEGF); (2) “progression” genes (e.g., PTGS2 (en-
codes COX-2) and MMP-1) that regulate extravasation of
circulating tumour cells and are involved in metastatic col-
onisation; (3) “virulence” genes (e.g., IL6 and TNFα), which
promote survival in circulation, and/or provide a prolifera-
tive advantage in the distant microenvironment. Apart from
these metastasis-promoting genes, there is a well-distin-
guished class of metastasis “suppressor” genes that represses
tumour cell dissemination without any eﬀect on primary
tumour growth, including KAI-1, BRSM1, and NME1 [11].
These ﬁndings are mainly derived from studies using animal
models. Historically, it has been diﬃcult to understand the
genetic alterations underlying metastasis by direct analysis
of human tissue. Transcriptomic proﬁling of matched pairs
of primary tumours and their metastases has demonstrated
a high degree of similarity with minor diﬀerential gene
expression [12–14]. However, the more recent application of
next-generationwholegenomesequencing(WGS)technolo-
gies is revealing subtle, but signiﬁcant distinctions between
metastases and their primary tumours of origin [15, 16] that
were previously undetectable.
2.What Is the Impactof BrainMetastasisin
the NaturalHistoryof Breast Cancer?
The prevalence of BM during the course of breast cancer
disease has been reported to range from 10%–16%, reaching
30% when autopsy diagnoses of BM are included [17, 18].
Several factors have been reported to be associated with
a higher risk of developing BM: patients less than ﬁfty
y e a r so l d ,f o u ro rm o r ea x i l l a r yl y m p hn o d e si n v o l v e dw i t h
metastatic disease, basal phenotype, and high tumour grade
[19–22].CurrenttherapeuticstrategiesforBMincludewhole
brain radiation therapy (WBRT; the treatment mainstay
since the 1950s), stereotactic radiosurgery, or surgery com-
bined with radiotherapy. The median survival in untreated
breast cancer patients with symptomatic BM is less than one
month, 6–8 weeks in patients treated with steroids alone and
3–6 months when treated with WBRT [3, 23].
Patients with HER2-positive breast tumours are now also
regarded to be at high risk for developing BM. Improved
control of systemic disease with the anti-HER2 monoclonal
antibody combined with poor BBB penetration have been
regarded as culprits of this increased metastatic trend [24].
BM treatment strategies are currently informed by the his-
topathology of the primary tumour, and BM are rarely bio-
psied. Whilst many features are shared, it is becoming clear
that metastases are distinct in their genetic landscape and
expression of critical disease markers [12, 14–16]. Hence,
future therapeutic development is likely to be based on fea-
tures of the metastases themselves.
3. Does the Incidence of BM Correlatewith
Breast CancerMolecularSubtypes?
Breast cancer is a heterogeneous disease with respect to mo-
lecular features perhaps best exempliﬁed by the molecular
subgroups identiﬁed by gene expression proﬁling including
basal-like,luminalA(hormonereceptorpositive),luminalB,
and HER2 ampliﬁed/over-expressed (HER2+) subtypes.
These molecular subtypes are associated with diﬀerent out-
comes. It is generally accepted that the basal-like, luminal B
and HER2+ subtypes are associated with particularly poor
prognosis compared with the hormone receptor-positive,
l uminalAsubtype[25,26](Figure 1).Basal-liketumoursare
generally high grade, have central areas of necrosis, invasive
pushing borders and are characterized by the expression
of markers including high-molecular weight cytokeratins
(e.g., CK14 and CK5/6), p53 and the myoepithelial markers
Smooth Muscle Actin (SMA) and p63 [27, 28].
We, and other groups, have reported a greater propensity
ofprimarybreastcancerwithabasal-likeimmunophenotype
to metastasize to the brain [20–22]. Moreover, patients with
germline BRCA1 mutations who develop breast cancer have
a higher incidence of BM compared to germline BRCA2 car-
riers and non-BRCA1/2 patients [29]. These tumours have
morphological similarities with those from the sporadic
basal-likegroup[27,28].PatientswithHER2+tumourshave
also been shown to have an increased incidence of BM [30].
These metastatic patterns were further validated by a large
study analysing, 3,726 cases, with a median follow-up of
14.8 years [31]. This work conﬁrmed a higher rate of BM
in HER2+-enriched and basal-like, compared to luminal A
tumours. The cumulative incidence for BM in basal-like and
HER2+ tumours were highest in the ﬁrst ﬁve years after
diagnosis, plateauing thereafter.Genetics Research International 3
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Figure 1: Summary of the major factors that increase or decrease risk of developing brain metastases in breast cancer and exciting new areas
of research that promise to deliver the knowledge required for new targeted therapies and better prognostication.
4. Current Understandingof BM from
Breast Cancer Mechanisms
Gene expression proﬁling of breast tumours coupled with
outcome data, functional analyses on cell lines, and in vivo
animal models have shed light on our understanding of the
colonization of the brain parenchyma by breast cancer cells
[10, 11, 16, 42–44]( Figure 1).
Regarding the brain microenvironment, there are two
main cell types in the neural tissue: neurons and glial cells,
including microglia, astroglia, and oligodendroglia. There is
a body of evidence suggesting that metastatic tumour cell
interactions with the brain microenvironment facilitate the
colonizationprocess[43].Interactionsbetweenbreastcancer
cells and pericytes and/or astrocytes might be responsible for
alterations in the BBB and thus, development of BM from
breast cancer. For example, Mendes et al. [45] reported that
astrocyte-induced factors activated the ERK1/2 signalling
pathway in rat mammary adenocarcinoma ENU1564 cells
andthusenhancedtheinvasivefeaturesofthesecellsthrough
increased expression of MMP-2. Furthermore, transfection
of ENU1564 cells with TIMP-2, a natural inhibitor of MMP-
2, reduced the in vitro invasive characteristics of these cells.
BM was not observed in animals inoculated with ENU1564-
TIMP-2, which implies a cardinal role for MMP-2 in BMBC
[45]. In addition, reactive glia under coculture with breast
cancer cell line MDA-MB-231 was shown to enhance growth
of this same cell line [46]. Furthermore, the 435-Br1 cell
line, which was derived from BM in a nude mouse, showed
increased adhesion to astrocytes and enhanced growth in
vitrointhepresenceofanastrocyte-conditionedmediawhen
compared to parental MDA-MB-435 breast cancer cells and
the lung metastasis-derived variant 435-Lung2 [47]. Table 1
summarizes BM-associated genes identiﬁed in integrated
studies that used combinations of in vitro cell culture-based
functional assays, in vivo mouse xenograft models and the
analysis of human clinical samples.
Palmieri et al. demonstrated that when human MDA-
MB-231-BR cells, the brain metastatic derivative of the
MDA-MB-231 cell line, were transfected with HER2, the
HER2-overexpressing clones showed a threefold increase in
the number of large BM compared with control MDA-MB-
231-BR cells [39]. These ﬁndings are consistent with epi-
demiological studies showing increased incidence of BM in
HER2+ breast cancer patients [30]. The same group showed
in vitro that Lapatinib inhibited the phosphorylation of
EGFR, HER2, and downstream signalling proteins leading to
reduced proliferation and migration in 231-BR. This in vitro
data was also replicated in a mouse model showing Lapatinib
inhibited the growth of brain macrometastases seeded from
EGFR-overexpressing 231-BR cells [48].
Another example of an integrated approach to under-
standing BM from breast cancer was published by Bos et al.
In this study, cyclooxygenase, the epidermal growth factor
receptor ligand HBEGF and α2,6-sialyltransferase acted as
mediators of cancer cell passage through the BBB. Again,
these ﬁndings were derived from in vitro functional analyses
and animal models, with translation in clinical samples
where meta-analysis of gene expression proﬁling of patients
who had brain metastases and survival data were combined.
The presence of this signature was related to shorter brain-
metastasis free survival [34].
Several studies focusing on the functional signiﬁcance
of single genes have also contributed to our current under-
standing of BM development. In an eﬀort to develop an ex-
perimental model of BM from breast cancer, Kim et al.
used internal carotid artery injection of breast cancer cells
into nude mice, which resulted in formation of diﬀerent
brain metastatic variant cell lines. These variants expressed
higher levels of vascular endothelial growth factor (VEGF)4 Genetics Research International
Table 1: Genes implicated in the development of brain metastases from breast cancer.
Gene abbrev Gene name BM expression
status Gene product functions Reference
KCNMA1 Potassium large conductance calcium-activated
channel, subfamily M, alpha member 1
↑ Voltage gated ion channel involved
in neuronal excitability [32]
MNT MAX binding protein ↓ Myc antagonist [33]
TERC Telomerase RNA component ↑ A template for telomere repeat [33]
CTSB Cathepsin B ↑ Lysosomal cysteine proteinase [33]
PTGS2 Prostaglandin-endoperoxide synthase 2 ↑ Prostaglandin biosynthesis [34]
HBEGF Heparin-binding EGF-like growth factor ↑ EGFR signalling [34]
ST6GALNAC5 ST6 N-acetylgalactosaminide
alpha-2,6-sialyltransferase 5
↑ Sialyltransferase that modiﬁes
proteins and ceramides [34]
CXCR4 Chemokine (C-X-C motif) receptor 4 ↑ Receptor for stromal cell-derived
factor-1 [35]
MMP2 Matrix metallopeptidase 2 ↑ Degradation of extracellular matrix [36]
MMP9 Matrix metallopeptidase 9 ↑ Degradation of extracellular matrix [36]
ROBO1 Roundabout ↑ Axon guidance and neuronal
precursor cell migration [37]
ERBB3 Y-erb-b2 erythroblastic leukemia viral
oncogene homolog 3
↑ Cell proliferation and
diﬀerentiation [12]
CAV1 Caveolin 1, caveolae protein ↓ Structural component of the
caveolae plasma membranes [38]
ERBB2 v-erb b2 erythroblastic leukemia viral
oncogene homolog 2
↑ Cell proliferation [39]
HK2 Hexokinase 2 ↑ Glycolysis [34]
HPSE Heparanase ↑ Remodeling of the extracellular
matrix [40]
STAT3 Signal transducer and activator of
transcription 3
↑
Cell growth and apoptosis,
inﬂammation, invasion, and
metastasis
[39]
VEGF Vascular endothelial growth factor ↑ Stimulates angiogenesis and
vasculogenesis [41]
IL-8 Interleukin 8 ↑ CXC chemokine involved in
neutrophil recruitment [41]
↑ overexpressed; ↓ downregulated.
and IL-8 than the nonbrain metastatic clones, suggesting
a possible role for VEGF in BM from breast cancer [40].
Consistent with this, suppression of BM and induction of
apoptosis were observed following treatment of the mice
with the VEGF-receptor tyrosine kinase inhibitor, PTK787/Z
222584 [40]. A second study by Palmieri et al. analyzed gene
expression proﬁles of laser-captured epithelial cells from
BM of breast cancer patients compared with unmatched
primary breast tumors. The results showed that hexokinase 2
(HK2), a critical enzyme in glucose metabolism, is increased
in BM [49]. Increased expression of HK2 was observed in
the 231-BR brain metastastic breast cancer cell line [49].
A third example is the study by Chiu et al., which showed
augmented expression of the activated form of signal trans-
ducer and activator of transcription 3 (STAT3)c o u p l e dw i t h
downregulation of Caveolin-1 (the structural component of
caveolaeinvolvedinmembranetraﬃckingandcellsignaling)
inBMcomparedwithprimarybreasttumours.Furthermore,
they showed that ectopic expression of Caveolin-1 or knock-
down of STAT3 reduces the invasive features of breast cancer
cells in vitro and brain colonization in vivo [38].
Ourgrouphascombinedgeneexpressionarrayproﬁling,
targeted somatic mutation analysis, and immunohistochem-
ical proﬁling of BM from breast cancer and integrated the
data to demonstrate activation of signaling pathways associ-
ated with the HER receptor family in BM compared to their
matched primary breast tumours. Critically, the data showed
an increase in HER3 expression in breast cancer cells isolated
from BM compared to matched primary tumours [12]. Neu-
regulin1,theligandforthisreceptor,isabundantlyexpressed
in the brain [50] and is activated by a variety of stimuli,
including hypoxia [51]. Consistent with this, we observed
increased expression of hypoxia-inducible Factor 1α (HIF-
1α) in the BM, likely reﬂecting the local hypoxic environ-
ment. Increased HER3 expression has also been reported
in BM from lung cancer [52]. These two clinical snapshots
could reﬂect environmental selection and therefore adap-
tation of metastatic cells to the brain microenvironment,
exploiting the Neuregulin-HER3 axis in order to succeed.
While there is ample evidence that miRNAs have deter-
minant roles in tumour cell dissemination, the possible roles
of these “micromanagers of metastasis” in BM from breastGenetics Research International 5
cancer are poorly understood. Using miRanda for target pre-
diction, Zhang et al. showed that miRNA-1258 targets he-
paranase (HPSE) which is the dominant endoglycosidase in
mammals. HPSE favors tumor cell spread through dissolu-
tion of the extracellular matrix. In addition, this study in-
troduced an inverse association between the miR-1258 levels
and heparanase expression and enzymatic activity [53].
These ﬁndings were conﬁrmed when the authors compared
miRNA-1258 levels in clinical samples of invasive ductal car-
cinoma and BMBC compared with the corresponding nor-
mal or primary tissues. Moreover, the expression of miR-
1258 in BM from breast cancer cells has been shown to sup-
press heparanase in vitro cell invasion and experimental BM.
5. The Blood-Brain-Barrier IsanAdditional
Challenge for BM Therapeutic Development
The BBB comprises a specialized endothelium surrounded
by a thick basement membrane and astrocytic endfeet [48].
Compared with endothelial cells from other vascular beds,
brain microvascular endothelial cells characteristically have
very low permeability to solutes and hydrophilic molecules,
high electrical resistance, complex tight junctions, and an
array of metabolic and transport systems that supply the
brain with nutrients and eliminate brain metabolic by-pro-
ducts. The low permeability is important in protecting the
brain from circulating toxins and restricting the migration of
leukocytes and monocytes, consequently it is also hindrance
to drug access. The BBB endothelia speciﬁcally express eﬄux
transporters that further diminish the brain availability of
certain chemotherapeutic agents, including p-glycoprotein,
breastcancerresistancep-glycoprotein,andmultidrugresist-
ance-associated protein [54]. Moreover, binding of speciﬁc
plasma proteins to chemotherapeutic drugs has been shown
to decrease the concentrations of such drugs and subse-
quently, delivery of these drugs to the brain [41]. Therefore,
poor drug delivery across the BBB is thought to be a major
factor underlying the limited eﬃciency of systemic chemo-
therapies against BM from breast cancer, particularly mon-
oclonal antibodies like Trastuzumab [48]. Large hydrophilic
molecules,suchaschemotherapeuticandmolecular-targeted
drugs, are excluded from the central nervous system unless
they can be actively transported by receptor-mediated tran-
scytosis. This highlights the need for new brain-permeable
drugs.
In order to metastasize to the brain, breast cancer cells
must attach to and invade through the BBB. A widely sup-
portedhypothesisisthatbreasttumourcelladhesioninduces
retraction of the endothelium, which exposes the vascular
basement membrane to the breast cancer cells. There is
ample evidence that breast cancer cells recognize and bind
to components in the vascular membrane, thereby initiating
extravasation and the beginning of colonization at secondary
organ sites [43]. The impairment of the BBB was observed
recently in breast cancer patients who developed metastasis
to the brain. CXCR4/SDF-1α has been suggested to play a
major role in penetration of breast cancer cells through brain
microvascular endothelial cells. In this regard, it has been
reported that SDF-1-α-mediated blood vessel instability via
enhanced vascular permeability facilitates BM from breast
cancer in a PI3K/Akt dependent manner [35].
The characteristics of the BBB necessitate the use of spe-
cialized, biologically relevant (and preferably throughput)
preclinical models to test the eﬃcacy of therapeutics against
BM. Neural-cancer cell co-cultures can be used to simulate a
brain-like microenvironment in vitro [55], but these simple
models do not test whether compounds could cross the BBB
in vivo. Bos and colleagues have developed a more biologi-
cally relevant in vitro transmigration assay, in which cancer
cells adhere to and migrate across a human umbilical vein
endothelial cell barrier towards human astrocytes segregated
in a transwell chamber [34]. The gold standard preclinical
model would involve xenograft transplantation of human
BM into immunocompromised mice, but development is
limited by the availability of fresh human tissue, and to our
knowledge, none have been developed using metastatic cells
selected in the human brain microenvironment. Alternative
models have been generated by in vivo selection of neu-
rotropicclonesinnudemice,followingintracardiacinjection
of metastatic cells from breast (231-BR, MCF7-HER2-BR,
CN34-BM, and the mouse mammary tumour-derived 4T1
syngeneic model) [56, 57]. Table 1 summarizes a series of
genes derived from integrated studies that have been impli-
cated in BM development.
6. Treatment StrategiesagainstMetastatic
Breast CancersIncludingBrainMetastases
We are approaching an era of personalized medicine, where
therapies will be routinely tailored to individual tumours
based on molecular diagnostics. Several targeted therapies
for metastatic breast cancer are currently used or in clinical
trials (Table 2; examples discussed below).
A recent phase II clinical trial using Lapatinib (dual in-
h i b i t o ro fH E R 1 / 2w i t hg o o db r a i np e n e t r a t i o n )i nH E R 2 +
breast cancer patients with BM despite prior radiation and
Trastuzumab therapy showed Lapatinib has modest CNS an-
titumour activity [68]. This was corroborated in a mouse
model where Lapatinib inhibited the colonisation of 231BR
cells overexpressing EGFR and HER2 [48]. There is also
evidence of synergism with Capecitabine, a pyrimidine an-
alogue prodrug approved for metastatic breast cancer man-
agement [41, 54]. Sunitinib, a multikinase inhibitor (targets
include VEGF-Rs, c-kit and PDGF-Rs), is also under investi-
gation for its eﬀects on BM in metastatic breast and renal cell
carcinomas [64, 65, 69].
7. Possible “Druggable” Targets for
the Future in BM from Breast Cancer
A recent study has demonstrated the role of STAT3 in BM
from breast cancer [38]. Moreover, it has been shown that
STAT3 inhibition by restoration of its inhibitor, suppressor
of cytokine signalling (SOCS-1), results in induction of
Caveolin-1, a tumour suppressor gene in breast cancer [38].
In this regard, STAT3 might be an attractive therapeutic
target in BM from breast cancer.6 Genetics Research International
Table 2: Current targeted therapies and their use in metastatic breast cancer (MBC).
Drug Class Targets Clinical indications Reference
Trastuzumab mAb HER2 Single agent for HER2+ MBC; used in combination
with paclitaxel as ﬁrst-line therapy for HER2+ MBC [58]
Lapatinib TKI HER1/2
Active in Trastuzumab-resistant, HER2+ breast
cancer; crosses the BBB and suppresses CNS
metastasis used in combination with Capecitabine
for HER2+ MBC
[41]
Pertuzumab mAb HER2
Impairs HER2 homo-/hetero-dimerisation; active in
Trastuzumab-resistant HER2+ breast cancers; not
currently approved for MBC
[59]
Neratinib TKI HER1/2
Inhibits HER2 autophosphorylation and suppresses
downstream signalling; active in HER2+ patients
with and without Trastuzumab pretreatment; not
currently approved for MBC
[60]
Bevacizumab mAb VEGF Antiangiogenic therapy for MBC in combination
with Docetaxel or Paclitaxel for ﬁrst-line treatment [61]
Sorafenib TKI
VEGFR
PDGFR
Raf
Multitarget receptor tyrosine kinase inhibitor;
FDA-approved for advanced renal cancer and
hepatocellular carcinoma
[62]
Axitinib TKI VEGFR
PDGFR
Currently in phase III clinical trial for metastatic
renal cell carcinoma [63]
Sunitinib TKI
VEGFR
PDGFR
KIT
Antiangiogenic therapy; FDA-approved for renal cell
carcinoma and Gleevec-resistant gastrointestinal
stromal tumours; eﬀective as a single agent for
metastatic breast cancer (phase II study)
[64–66]
Pazopanib TKI
VEGFR
PDGFR
KIT
Anti-angiogenic therapy; FDA-approved for renal
cell carcinoma; combination with Lapatinib has
superior activity as the ﬁrst-line treatment for MBC
(phase II study)
[67]
Abbreviations: BBB: blood-brain barrier; CNS: central nervous system; HER1: Epidermal Growth Factor Receptor (EGFR); mAb: monoclonal antibody; KIT:
Mast/stem cell growth factor receptor gene; PDGFR: platelet-derived growth factor receptor; TKI: tyrosine kinase inhibitor; VEGFR: vascular endothelial
growth factor receptor.
Secondly, a growing body of evidence suggests that he-
paranase, a downstream target of EGFR/HER2, might be
involved in BM from breast cancer [53]. EGF induces nu-
cleolar translocation of HPSE and induction of DNA topoi-
somerase I which is essential for BM from breast cancer and
cell proliferation [53]. In this setting, heparanase has been
suggested as a potential target that could be exploited thera-
peutically [53].
Palmieri et al. [49] reported that hexokinase 2 (HK2) is
signiﬁcantly increased in brain metastases compared to un-
matched primary breast tumors. Hexokinases phosphorylate
glucose to produce glucose-6-phosphate in the ﬁrst step of
glucose metabolism. It is thought that HK2 increases glycol-
ysis in tumor cells and may therefore be an attractive thera-
peutic target [49].
We recently identiﬁed somatic activating mutations in
genes associated with the AKT and MAPK signaling path-
ways, including PIK3CA, KRAS, HRAS,a n dNRAS,i nB M
from breast and other cancers[12].This highlights the possi-
bility of cancer cells resisting targeted treatment to molecules
such as HER2 or EGFR by acquiring oncogenic mutations
in downstream pathways. Therapeutic modalities targeting
these downstream pathways are currently being investigated
[59]. In addition, Grigoriadis et al. demonstrated the pres-
ence of CT-X antigens in a cohort of BM, including BM from
breast cancer. These proteins are predominantly expressed in
human germ cells and not somatic tissues, but are frequently
activated in cancer. Nearly two-thirds of our BM cohort
showed expression of MAGE-A and NY-ESO, two of the CT-
X antigens for which inhibitors are currently in clinical trials
for lung cancer and melanoma [70]. Targeting these antigens
could therefore also be an eﬀective therapeutic strategy for
BM.
8. FutureDirections:BrainMetastases inthe
Whole Genome Sequencing Era
Direct, high-resolution genomic and transcriptomic analyses
of BM may uncover new druggable features that can be tar-
geted to speciﬁcally inhibit BM cells. The development and
continual reﬁnement of WGS technologies has dramatically
increased the resolution with which we can analyse cancer
genomes. We can now screen for new mutations, simulta-
neously and accurately assess their frequencies and correlate
this with expression data across the entire genome. Rare mu-
tations, that are present in only a small percentage of cells
within the heterogeneous primary tumour mass, may be im-
portant in progression and virulence acquisition at a meta-
static site. Although there are no large-scale BM genomics
studies published to date, Ding and colleagues used WGSGenetics Research International 7
to interrogate the genomic proﬁles of a human BM, its cor-
responding primary breast tumour, and a mouse xenograft
derivative [44]. They showed that; (1) most of the genomic
changes present in the primary tumour are propagated dur-
ing the clinical course of the disease; (2) the frequency of
some mutations was increased in the BM, suggesting enrich-
ment with a subpopulation of cells selected from a more het-
erogeneous primary tumour; (3) two diﬀerent populations
of cells from the primary tumour, with distinct subsets of
mutations, were selected during the metastatic process. The
third ﬁnding is striking and is consistent with other data
suggesting that metastases may be established from clusters
of cells, rather than one founder cell [71]o rm a yd e r i v ef r o m
regions of the tumour where there is clonal heterogeneity
[16].
9. Conclusions
Thus far, we have only fragmented knowledge of the mecha-
nisms underlying breast cancer cell colonisation of the brain
microenvironment.Animalmodelsandgeneexpressionpro-
ﬁling have and will continue to provide insight, however it
is anticipated that next-generation sequencing technology
and integration of this data with expression proﬁling will
enable us to generate a comprehensive map of the brain me-
tastasis genomic landscape. To be able to translate this im-
pendingknowledgeintoclinicaloutcomes,wemustcontinue
to develop and reﬁne high-throughput, biologically relevant
preclinical models that accurately mimic the brain microen-
vironment and the BBB (summarized in Figure 1).
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